jueves, 27 de noviembre de 2014

The Access to medicine Index 2014

"...al fin de cuentas, 
las empresas farmacéuticas no se dedican 
a la actividad empresarial 
empujadas por la bondad dentro de sus corazones, 
y no hay dinero que ganar en la prevención 
y curación de las enfermedades de los pobres." 

Joseph E. Stiglitz, Univ.de Columbia 
Premio Nobel de Economía 2001
The Access to Medicine Index (descargar) independently ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries. Funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments, the Index has been published every two years since 2008.


 The Access to Medicine Index 2010

 The Access to Medicine Index 2012

The access to medicine problem is multifaceted, and responsibility for tackling it lies with many different actors - governments, NGOs, academia, pharmaceutical companies, finance institutions and multilateral organisations such as the WHO. As manufacturers and developers of life-saving products, pharmaceutical companies clearly have a crucial role to play.

 Click sobre imagen para ampliar

Why an Index? 

The Index publicly recognises companies for their investments in access to medicine, raising awareness of relevant issues within pharmaceutical companies and providing them with a transparent means by which they can assess, monitor and improve their own performance as well as their public and investment profiles. Consistent iterations of the Index highlight industry trends and provide a basis for multi-stakeholder dialogue and solution building.

Five companies are developing more than half of the products in the pipeline for developing countries.

The top 20 pharmaceutical companies are developing 327 relevant products, with only five companies (Novartis, J&J, GSK, AbbVie and Sanofi) accounting for more than half the pipeline and more than half the products targeting only five diseases. 

Compared to 2012, pricing strategies are increasingly tailored, as more companies take account of socioeconomic factors, such as ability to pay. Importantly, more companies are setting different prices for different segments of national populations.

No hay comentarios: